Coelenterazine analogues
Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
1. A method for in vivo bioluminescent imaging, the method comprising:
contacting a live cell with a compound of Formula I or Formula II:
wherein R 5 and R 5a are hydrogen;
R 6 and R 6a are aryl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, acyl amino, aminoalkyl, alkyl, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, alkoxy, sulfonylamino, sulfonyl, alkylsulfonyl, amide, carbamate, silyl, substituted silyl, acyl, or aminosulfonyl;
R 8 and R 8a are optionally substituted aryl, heteroaryl, alkyl substituted with aryl, or alkyl substituted with heteroaryl;
R x is halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, alkoxy, or heteroalkyl; and
p is 0, 1, 2, 3, 4, or 5;
provided that the following compounds are excluded from formula (I): 8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one; and
8-benzyl-2-(furan-2-ylmethyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one; and
R x is not 4-hydroxy when p is 1, R 5a is not hydrogen, or R 8a is not benzyl, or any combination thereof;
and
detecting luminescence; wherein the live cell expresses a coelenterazine-utilizing luciferase.
2. The method of claim 1 , wherein:
R 6 and R 6a are phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, acyl amino, aminoalkyl, alkyl, fluoroalkyl, alkoxyfluoroalkyl, fluoroalkoxy, alkenyl, alkynyl, haloalkyl, haloalkoxy, heteroalkyl, alkoxy, sulfonylamino, sulfonyl, alkylsulfonyl, amide, carbamate, silyl, substituted silyl, acyl, or aminosulfonyl.
3. The method of claim 1 , wherein
R 6 and R 6a are
X 1 -X 5 are each independently CR 11 ; and
R 11 , at each occurrence, is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, amino, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, and C 1 -C 6 -heteroalkyl.
4. The method of claim 3 , wherein R 8 and R 8a are selected from the group consisting of:
5. The method of claim 3 , wherein the compound is of formula (I); R 11 at X 1 , X 3 , X 4 , and X 5 is hydrogen; and the R 11 at X 2 is hydrogen, hydroxy, amino, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 1 -C 6 -alkylamino, C 1 -C 6 -dialkylamino, or C 1 -C 6 -heteroalkyl.
6. The method of claim 3 , wherein the compound is of formula (I); and R 6 is selected from the group consisting of:
7. The method of claim 5 , wherein R 8 is selected from the group consisting of:
8. The method of claim 5 , wherein R 8 is
9. The method of claim 7 , wherein the compound is
10. The method of claim 1 , wherein the live cell is in an animal.
11. The method of claim 1 , wherein the coelenterazine-utilizing luciferase is selected from the group of a Oplophorus luciferase or variant thereof and a Renilla luciferase or a variant thereof.
12. The method of claim 1 , wherein the coelenterazine-utilizing luciferase is expressed as a fusion protein.
13. The method of claim 12 , wherein the fusion protein comprises the coelenterazine-utilizing luciferase and a protein of interest.
14. The method of claim 13 , wherein the coelenterazine-utilizing luciferase is selected from the group of a Oplophorus luciferase or variant thereof and a Renilla luciferase or a variant therof.